Overview

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
6-Mercaptopurine
Asparaginase
BB 1101
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Mercaptopurine
Methotrexate
Pegaspargase
Pirarubicin
Prednisone
Vincristine